RMTI Rockwell Medical

Rockwell Medical Shareholders Give Mark H. Ravich Sweeping Mandate for Change

Richmond Brothers, Inc. (“Richmond Brothers”), a Michigan-based SEC registered investment advisor and wealth management firm that is the largest beneficial owner of Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell” or the “Company”), which together with its affiliates beneficially owns over 5.6 million shares, or 10.9% of the Company’s outstanding common stock, today announced that final certified vote totals from inspector of elections IVS Associates, Inc. show that Richmond Brothers’ highly-qualified nominee, Mark H. Ravich, received support from over 66% of the votes cast – and more than half of the Company’s outstanding shares – at the 2017 Annual Meeting of Shareholders, which was held on June 1, 2017.

David S. Richmond, Chairman of Richmond Brothers issued the following statement commenting on the final results:

“We are extremely grateful to the many Rockwell shareholders who have voiced their strong support for change at Rockwell by electing our nominee, Mark H. Ravich. The finalized vote tally, indicating that nearly two-thirds of the votes cast, and more than 50% of all of the Company’s outstanding shares, went to Mark – speaks volumes about the extent of shareholders’ frustrations with Rockwell’s Board and management. Excluding shares voted by insiders, the results are even more staggering. It is our sincere hope that Rockwell takes heed of this unequivocal result and begins working immediately to rectify the performance and governance issues that have plagued the Company for years.”

For more information, and to see other communications and filings from Richmond Brothers, visit this link: http://www.richmondbrothers.com/time-for-action-at-rmti.

About Richmond Brothers, Inc.

Richmond Brothers, Inc. is an SEC registered investment advisor and wealth management firm founded in 1994.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Rockwell Medical

 PRESS RELEASE

Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...

 PRESS RELEASE

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...

 PRESS RELEASE

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...

Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...

Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...

 PRESS RELEASE

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch